Treatment Efficacy Scored-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials

Article Medicine, General & Internal

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

P. Schmid et al.

Summary: The addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab after surgery significantly prolonged event-free survival in patients with early triple-negative breast cancer.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Multidisciplinary Sciences

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

Amy S. Clark et al.

Summary: HER2-targeted therapy significantly improves outcomes in early breast cancer patients. Two HER2-targeted combinations have shown promising efficacy in early breast cancer patients at high risk of recurrence, potentially aiding in identifying patients who can safely reduce cytotoxic chemotherapy without compromising outcomes.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Oncology

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

Douglas Yee et al.

Summary: The study found that further development of anti-IGF-1R therapy will require better control of drug-induced hyperglycemia and the development of more predictive biomarkers.

NPJ BREAST CANCER (2021)

Add to Collection

Article Oncology

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

Lajos Pusztai et al.

Summary: The combination of PD-L1 inhibitor durvalumab and PARP inhibitor olaparib with standard paclitaxel neoadjuvant chemotherapy showed superior efficacy in treating HER2-negative breast cancer, especially in a subset of high-risk HR-positive/HER2-negative patients.

CANCER CELL (2021)

Add to Collection

Article Oncology

Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer An Analysis of Data From the I-SPY2 Randomized Clinical Trial

W. Fraser Symmans et al.

Summary: The study compared RCB distributions and found a positive correlation between RCB and event-free survival (EFS) in different subtypes of breast cancer. Investigational treatments significantly reduced RCB and improved EFS, providing important information for interpreting treatment efficacy.

JAMA ONCOLOGY (2021)

Add to Collection

Article Oncology